JG-231 is a JG-98 analog with anticancer activity.JG-231 inhibits the MDA-MB-231 xenograft tumor model of triple-negative breast cancer (TNBC).JG-231 inhibits the interaction of Hsp70-BAG3.JG-231 inhibits the MDA-MB-231 xenograft tumor model of triple-negative breast cancer (TNBC). JG-231 inhibits MDA-MB-231 xenograft tumor model of triple negative breast cancer (TNBC).

98%

Store at -20℃ for one year（Powder）；Store at 2-4℃ for two weeks；Store at -20℃ for six months after dissolution.

DMSO:1.8 mg/mL (2.9 mM)

JG-231 (2, 4 mg/kg; administered intraperitoneally) effectively suppressed the growth of A375, A375-PLX/R, and Colo829 xenografts in athymic nude mice without causing significant body weight loss. JG231-treated tumors exhibited increased lamin A cleavage and p21CIP1 expression. Moreover, JG231-treated tumors also exhibited increased MEK1/2 phosphorylation.[3]